Plasma Glutathione and Prodromal Parkinson's Disease Probability

Mov Disord. 2022 Jan;37(1):200-205. doi: 10.1002/mds.28826. Epub 2021 Oct 25.

Abstract

Background: A decrease in glutathione (GSH) levels is considered one of the earliest biochemical changes in Parkinson's disease (PD).

Objective: The authors explored the potential role of plasma GSH as a risk/susceptibility biomarker for prodromal PD (pPD) by examining its longitudinal associations with pPD probability trajectories.

Methods: A total of 405 community-dwelling participants (median age [interquartile range] = 73.2 [7.41] years) without clinical features of parkinsonism were followed for a mean (standard deviation) of 3.0 (0.9) years.

Results: A 1 μmol/L increase in plasma GSH was associated with 0.4% (95% confidence interval [CI], 0.1%-0.7%; P = 0.017) less increase in pPD probability for 1 year of follow-up. Compared with participants in the lowest GSH tertile, participants in the highest GSH tertile had a 12.9% (95% CI, 22.4%-2.2%; P = 0.020) slower rate of increase of pPD probability for 1 year of follow-up.

Conclusion: Plasma GSH was associated with pPD probability trajectories; therefore, it might assist in the identification of individuals who are likely to reach the threshold for pPD diagnosis more rapidly. © 2021 International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; oxidative stress; plasma glutathione; prodromal Parkinson's disease; redox biomarkers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Glutathione* / blood
  • Humans
  • Parkinson Disease* / blood
  • Parkinson Disease* / diagnosis
  • Probability
  • Prodromal Symptoms*

Substances

  • Glutathione